Insulin Makers Cap Prices for Insured Individuals
THREE DRUGMAKERS, which account for roughly 90% of the insulin in the U.S. market, in March 2023 announced that they will cap the cost of insulin. That includes those on employer-sponsored group health plans and plans purchased on a government-run exchange. The changes mean some or many of your employees will see significant reductions in their pharmaceutical outlays, particularly if they have high copays or deductibles.
July 24, 2023